VITA 34 International AG: VITA 34 plans further growth in 2011 and international expansion

Sales forecast of more than 18m Euro for 2011

28-Mar-2011 - The VITA 34 International AG wants to continue its growth in the current business year 2011 and aims at increasing the revenue from approximately 17m Euro in 2010 to more than 18m Euro. It is also intended to further increase the number of storages. With 11,038 umbilical cord blood storages in ...

VITA 34 and Hannover Medical School start project on iPS cells

09-Jun-2010 - VITA 34 International AG starts a joint research project on the production of so-called induced pluripotent stem cells (iPS cells) from umbilical cord blood in cooperation with the Hannover Medical School (MHH). In this project, VITA 34 and a MHH team under management of Prof. Dr. Ulrich Martin ...

VITA 34 has taken over majority in Spanish partner Secuvita

18-May-2010 - The VITA 34 International AG tightens its presence in the Spanish market and is now the indirect holder of 51.62 percent of the shares in the Spanish corporation Secuvita, S.L. by having taken over all of the company shares of the Novel Pharma S.L.. A purchase price at the amount of about 3 ...

VITA 34 International AG restructures management team after returning to the black

Streamlined structure aimed at further increasing profitability

22-Oct-2009 - VITA 34 International AG has decided to restructure its management team after successfully returning to the black. This move is to lay the foundations for further increasing profitability in the coming years. Dr. Eberhard Lampeter, founder and CEO of VITA 34 AG, will continue to head the ...

VITA 34: Positive Results in Q2 2009

15-Jul-2009 - VITA 34 International AG, the parent company of the umbilical cord blood bank in the German-speaking countries, VITA 34, has returned to profitability in the second quarter of 2009. The earnings before interest and taxes (EBIT) improved to more than EUR 16k following a loss of EUR 0.8 million in ...

Embryonale Stammzellen mit tierischem Genmaterial verunreinigt

02-Feb-2005 - Alle embryonalen Stammzellen, an denen derzeit geforscht wird, sind nicht zur Behandlung von Menschen geeignet. Das ist das ernüchternde Ergebnis einer US-Studie, die jetzt im Fachmagazin Nature Medicine veröffentlicht wurde. Grund ist die falsche "Ernährung" der embryonalen Stammzellen. "Genau ...